Equities

Synsam AB (publ)

Synsam AB (publ)

Actions
Consumer DiscretionaryConsumer Discretionary
  • Price (SEK)52.30
  • Today's Change-1.60 / -2.97%
  • Shares traded80.68k
  • 1 Year change+23.06%
  • Beta--
Data delayed at least 15 minutes, as of May 15 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Synsam AB (publ) is a Sweden-based lifestyle company in optical retail and eye health. The Company operates stores in Sweden, Denmark, Norway, Finland, Iceland and the Faroe Islands. The store network is complemented by a presence online presence via Synsam, Profil Optik and Ai's own websites and social media, where customers can buy products, book eye exams, manage their subscriptions, or try glasses directly in the mobile phone. The Company has a range of glasses, sunglasses, sports glasses and contact lenses that include both Synsam’s own and other well-known brands. The offering also includes glasses and contact lens subscriptions, eye examinations, both physical and online, and personal style advice when trying on glasses.

  • Revenue in SEK (TTM)5.91bn
  • Net income in SEK311.00m
  • Incorporated1968
  • Employees3.41k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Stille AB362.16m35.58m1.82bn142.0033.662.8134.035.016.006.0060.2071.840.53641.777.183,416,557.005.277.036.358.1946.7643.939.829.850.98797.170.0021.9819.7016.78-2.485.3423.62--
Bactiguard Holding AB220.81m-126.19m2.17bn191.00--7.14--9.84-3.60-3.606.309.800.30354.286.001,017,544.00-17.35-7.56-19.82-8.8129.8747.91-57.15-26.281.64-11.900.4129---11.966.46-161.71--8.43--
Sedana Medical AB (publ)164.91m-22.83m2.30bn83.00--2.3333,891.4313.98-0.2299-0.22991.669.950.15641.248.102,087,443.00-2.17-5.77-2.28-6.0870.5064.06-13.85-36.137.38--0.0043--25.2321.5918.90--42.12--
Detection Technology Oyj-1.17tn-1.17tn2.69bn478.00--3.16----------4.97----------9.34--11.96--47.44--8.223.13--0.08153.455.292.027.55-18.03-14.88-9.55
BICO Group AB2.25bn-1.70bn3.18bn884.00--0.6649--1.41-23.61-27.6631.6069.180.24872.243.062,545,136.00-18.77---20.89--52.34---75.47--1.91-1.050.2852--6.09---1,889.33------
Medistim ASA530.30m102.42m3.22bn152.0031.417.5025.466.085.605.6029.0123.481.030.77656.153,492,704.0019.9522.9324.0728.5279.0278.2519.3120.642.99--0.020675.257.0010.06-8.9112.720.03314.87
CellaVision AB708.28m141.22m5.47bn223.0038.767.2130.097.735.925.9229.6931.810.7571.688.453,106,469.0015.0915.3017.3418.2467.5269.0319.9419.982.2166.290.0688110.185.9413.1710.128.0030.458.45
Synsam AB (publ)5.91bn311.00m8.09bn3.41k25.833.187.661.372.092.0939.6216.960.73562.2213.121,730,149.003.86--5.27--75.50--5.25--0.4922--0.5675--11.90---5.18------
Revenio Group Oyj1.13bn222.20m8.68bn216.0038.647.4132.367.680.72050.72053.663.760.70695.507.60447,574.1013.9014.3316.7717.9051.0150.7319.6621.131.7928.490.152155.81-0.412525.80-12.1518.7217.676.30
Xvivo Perfusion AB642.95m100.43m12.30bn148.00117.736.1474.6219.133.323.3221.1863.590.3221.284.274,018,431.005.031.245.491.3373.9473.1415.624.763.40--0.01520.0043.8826.04398.2948.5721.35--
Arjo AB (publ)11.10bn518.00m12.58bn6.71k26.031.678.121.131.901.9040.7629.720.69114.156.311,632,980.003.213.554.445.5543.4344.014.645.410.69134.140.402443.0110.035.976.9010.15-8.8910.35
Biotage AB1.98bn236.00m13.72bn669.0056.963.5334.056.933.013.0125.5748.610.52762.017.782,939,169.006.2910.747.3312.7762.1961.3411.9115.771.528.950.06240.1118.9015.37-8.217.9714.051.30
Embla Medical hf8.69bn614.99m19.24bn4.00k31.212.4316.472.210.92030.920312.9911.810.55822.206.601,386,978.003.964.064.684.7661.4162.477.096.911.075.810.43253.999.335.0937.34-6.056.50--
Data as of May 15 2024. Currency figures normalised to Synsam AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

32.18%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 31 Dec 20229.09m6.06%
Carnegie Fonder ABas of 06 Mar 20248.20m5.47%
Handelsbanken Fonder ABas of 06 Mar 20248.11m5.40%
Mawer Investment Management Ltd.as of 31 Dec 20227.86m5.24%
C Worldwide Asset Management Fondsm�glerselskab A/S (Sweden)as of 31 Dec 20226.29m4.19%
Candriam Belgium SAas of 31 Jan 20242.53m1.69%
Norges Bank Investment Managementas of 31 Dec 20222.29m1.53%
Oddo BHF Asset Management SASas of 28 Mar 20241.94m1.30%
Svenska Handelsbanken AB (Private Banking)as of 31 Dec 20221.04m0.69%
Fondita Fund Management Co. Ltd.as of 31 Dec 2022933.57k0.62%
More ▼
Data from 31 Dec 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.